Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | GGPS1 | O95749 | 6/20 | 0.35 |
| ▸ | FDPS | P14324 | 9/20 | 0.34 |
| ▸ | SMPD1 | P17405 | 2/20 | 0.33 |
| ▸ | CES2 | O00748 | 1/20 | 0.33 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.33 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19798171 | 0.82 | TSHR (0.35) | TSHRTHRBGGPS1FDPSSMPD1 | |
| SCHEMBL18671809 | 0.82 | L3MBTL1 (0.35) | TSHRTHRBGGPS1FDPS | |
| SCHEMBL22921027 | 0.82 | L3MBTL1 (0.35) | TSHRTHRBGGPS1FDPS | |
| SCHEMBL5295320 | 0.82 | L3MBTL1 (0.35) | TSHRTHRBGGPS1FDPS | |
| SCHEMBL28483075 | 0.82 | L3MBTL1 (0.35) | TSHRTHRBGGPS1FDPS | |
| SCHEMBL24276317 | 0.80 | L3MBTL1 (0.37) | TSHRTHRBGGPS1FDPS | |
| SCHEMBL22023942 | 0.80 | L3MBTL1 (0.37) | TSHRTHRBGGPS1FDPS | |
| SCHEMBL20877870 | 0.80 | L3MBTL1 (0.37) | TSHRTHRBGGPS1FDPS | |
| SCHEMBL27501976 | 0.80 | TSHR (0.33) | TSHRTHRBGGPS1FDPS | |
| SCHEMBL24130892 | 0.79 | GNAO1 (0.38) | TSHRTHRBGGPS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7214842-B2 | Method for oligomerizing olefins | BASF AKTIENGESELLSCHAFT (DE) | 2007-05-08 | — | — | US | disclosed |
| US-20050165266-A1 | olefin is brought into contact with a catalyst system comprising at least one transition metal complex with a polydentate complexing ligand and an alkylaluminoxane; transition metal complex is added continuously or in portions during the oligomerization. | BASF AKTIENGESELLSCHAFT (DE) | 2005-07-28 | — | — | US | disclosed |
| US-6844290-B1 | Oligomerization catalyst | BASF AKTIENGESELLSCHAFT (DE) | 2005-01-18 | — | — | US | disclosed |
| EP-1171445-B1 | OLIGOMERISATION CATALYST | BASF AG (DE) | 2004-01-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050165266-A1 | olefin is brought into contact with a catalyst system comprising at least one transition metal complex with a polydentate complexing ligand and an alkylaluminoxane; transition metal complex is added continuously or in portions during the oligomerization. | ALOX12, ALOX15B, ALOX15 | TSHR 3306/4885THRB 3354/4885GGPS1 1303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.